Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBF 1120 versus sorafenib in advanced hepatocellular carcinoma
NL-OMON39531Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nintedanib and sorafenib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Time to progression. Started Sep 2012; status: active, not recruiting.
02
Drugs
nintedanibsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NL-OMON39531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39531.